Misplaced Pages

Sarecycline

Clinical data
Pronunciation	sar"e sye' kleen
Trade names	Seysara
Other names	P-005672
AHFS/Drugs.com	Monograph
MedlinePlus	a618068
License data	US DailyMed: Sarecycline
Routes of administration	By mouth
ATC code	J01AA14 (WHO) J01AA20 (WHO)
Legal status
Legal status	US: ℞-only
Identifiers
IUPAC name (4S,4aS,5aR,12aR)-4-(Dimethylamino)-1,10,11,12a-tetrahydroxy-7-methyl]-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide
CAS Number	1035654-66-0
PubChem CID	54681908 as HCl: 71296095
DrugBank	DB12035 as HCl: DBSALT002125
ChemSpider	28540486
UNII	94O110CX2E
KEGG	D10666 as HCl: D10667
ChEMBL	ChEMBL2364632
PDB ligand	V7A (PDBe, RCSB PDB)
CompTox Dashboard (EPA)	DTXSID001027924
ECHA InfoCard	100.241.852
Chemical and physical data
Formula	C24H29N3O8
Molar mass	487.509 g·mol
3D model (JSmol)	Interactive image
SMILES CN(C)12C3CC4=C(C=CC(=C4C(=C3C(=O)2(C(=C(C1=O)C(=O)N)O)O)O)O)CN(C)OC

Sarecycline, sold under the brand name Seysara, is a narrow-spectrum tetracycline-derived antibiotic medication. It is specifically designed for the treatment of acne, and was approved by the FDA in October 2018 for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older. Two randomized and well-controlled clinical trials reported efficacy data on both facial and truncal acne (back and chest). Efficacy was assessed in a total of 2002 subjects 9 years of age and older. Unlike other tetracycline-class antibiotics, sarecycline has a long C7 moiety that extends into and directly interact with the bacterial messenger RNA (mRNA). The spectrum of activity is limited to clinically relevant Gram-positive bacteria, mainly Cutibacterium acnes, with little or no activity against Gram-negative bacterial microflora commonly found in the human gastrointestinal tract.

Medical uses

Sarecycline, is indicated for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.

References

1. ^ "Seysara- sarecycline hydrochloride tablet, coated". DailyMed. U.S. National Library of Medicine. 1 August 2021. Retrieved 31 March 2023.
2. Zhanel G, Critchley I, Lin LY, Alvandi N (January 2019). "Microbiological Profile of Sarecycline, a Novel Targeted Spectrum Tetracycline for the Treatment of Acne Vulgaris". Antimicrobial Agents and Chemotherapy. 63 (1). doi:10.1128/AAC.01297-18. PMC 6325184. PMID 30397052.
3. "Sarecycline". PubChem. U.S. National Library of Medicine. Retrieved 5 September 2020.
4. Moore A, Green LJ, Bruce S, Sadick N, Tschen E, Werschler P, et al. (September 2018). "Once-Daily Oral Sarecycline 1.5 mg/kg/day Is Effective for Moderate to Severe Acne Vulgaris: Results from Two Identically Designed, Phase 3, Randomized, Double-Blind Clinical Trials". Journal of Drugs in Dermatology. 17 (9): 987–996. PMID 30235387.
5. Batool Z, Lomakin IB, Polikanov YS, Bunick CG (August 2020). "Sarecycline interferes with tRNA accommodation and tethers mRNA to the 70S ribosome". Proceedings of the National Academy of Sciences of the United States of America. 117 (34): 20530–20537. Bibcode:2020PNAS..11720530B. doi:10.1073/pnas.2008671117. PMC 7456112. PMID 32817463.
6. Zhanel G, Critchley I, Lin LY, Alvandi N (January 2019). "Microbiological Profile of Sarecycline, a Novel Targeted Spectrum Tetracycline for the Treatment of Acne Vulgaris". Antimicrobial Agents and Chemotherapy. 63 (1). doi:10.1128/AAC.01297-18. PMC 6325184. PMID 30397052.

• Medicine

This antiinfective drug article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Tetracycline antibiotics
• Antiinfective agent stubs